Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial - 03/12/19

Doi : 10.1016/S1470-2045(19)30486-3 
Christian Carrie, MD a, b, , Nicolas Magné, ProfMD c, Patricia Burban-Provost, MD d, Paul Sargos, MD e, Igor Latorzeff, MD f, Jean-Léon Lagrange, ProfMD g, Stéphane Supiot, PhD h, Yazid Belkacemi, ProfMD i, Didier Peiffert, ProfMD j, Nedla Allouache, MD k, Bernard M Dubray, ProfMD l, Stéphanie Servagi-Vernat, PhD m, Jean-Philippe Suchaud, MD n, Gilles Crehange, PhD o, Stéphane Guerif, MD p, Meryem Brihoum, MSc q, Nicolas Barbier, MD r, Pierre Graff-Cailleaud, PhD s, Alain Ruffion, ProfMD t, Sophie Dussart, MD u, Céline Ferlay, MSc u, Sylvie Chabaud, MSc u
a Radiotherapy Department, Léon Bérard Center, Lyon, France 
b CNRS UMR 5220, INSERM U1044, INSA, University of Lyon, Lyon, France 
c Cellular and Molecular Radiobiology, Lucien Neuwirth Cancer Institute, and Institute of Nuclear Physics of Lyon, Lyon-Sud Faculty of Medicine, Lyon, France 
d private hospital of Cotes D’armor, Plerin, France 
e Radiotherapy Department, Bergonié Institute, Bordeaux, France 
f Clinique Pasteur Groupe Oncorad Garonne, Toulouse, France 
g Henri Mondor Breast Center, Créteil, France 
h René Gauducheau cancer Institute, Nantes, France 
i Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris-Est, Créteil, France 
j Lorraine Cancer Institute, Alexis Vautrin Cancer Center, Université de Lorraine, Faculté de Médecine, Vandoeuvre-les-Nancy, France 
k François Baclesse Cancer Center, Caen, France 
l Henri Becquerel Cancer Center, Rouen, France 
m Jean Godinot Institute, Reims, France 
n Radiotherapy Department, Roanne hospital center, Roanne, France 
o Georges-François Leclerc Cancer Center, Dijon, France 
p University hospital of Poitiers, Poitiers, France 
q UNICANCER, Paris, France 
r Catalan Cancer Center, Perpignan, France 
s University Institute of Cancer Toulouse-Oncopôle, Toulouse, France 
t Urology Department, Hospices Civils de Lyon, Pierre-Bénite, France 
u Biostatistics Unit, Clinical Research and Innovation Department, Léon Bérard Cancer Centre, Lyon, France 

* Correspondence to: Dr Christian Carrie, Radiotherapy Department, Centre Léon Bérard, 69008 Lyon, France Radiotherapy Department Centre Léon Bérard Lyon 69008 France



Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone.


GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease. Patients were assigned through central randomisation (1:1) to short-term androgen suppression (subcutaneous injection of 10·8 mg goserelin on the first day of irradiation and 3 months later) plus radiotherapy (3D conformal radiotherapy or intensity modulated radiotherapy of 66 Gy in 33 fractions, 5 days a week for 7 weeks) or radiotherapy alone. Randomisation was stratified using a permuted block method (block sizes of two and four) according to investigational site, radiotherapy modality, and prognosis. The primary endpoint was progression-free survival in the intention-to-treat population. This post-hoc one-shot data collection done 4 years after last data cutoff included patients who were alive at the time of the primary analysis and updated long-term patient status by including dates for first local progression, metastatic disease diagnosis, or death (if any of these had occurred) or the date of the last tumour evaluation or last PSA measurement. Survival at 120 months was reported. Late serious adverse effects were assessed. This trial is registered on ClinicalTrials.gov, NCT00423475.


Between Oct 19, 2006, and March 30, 2010, 743 patients were randomly assigned, 374 to radiotherapy alone and 369 to radiotherapy plus goserelin. At the time of data cutoff (March 12, 2019), the median follow-up was 112 months (IQR 102–123). The 120-month progression-free survival was 64% (95% CI 58–69) for patients treated with radiotherapy plus goserelin and 49% (43–54) for patients treated with radiotherapy alone (hazard ratio 0·54, 0·43–0·68; stratified log-rank test p<0·0001). Two cases of secondary cancer occurred since the primary analysis, but were not considered to be treatment related. No treatment-related deaths occurred.


The 120-month progression-free survival confirmed the results from the primary analysis. Salvage radiotherapy combined with short-term androgen suppression significantly reduced risk of biochemical or clinical progression and death compared with salvage radiotherapy alone. The results of the GETUG-AFU 16 trial confirm the efficacy of androgen suppression plus radiotherapy as salvage treatment in patients with increasing PSA concentration after radical prostatectomy for prostate cancer.


The French Health ministry, AstraZeneca, la Ligue Contre le Cancer, and La Ligue de Haute-Savoie.

Le texte complet de cet article est disponible en PDF.


© 2019  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 12

P. 1740-1749 - décembre 2019 Retour au numéro
Article précédent Article précédent
  • Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
  • Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger, Bernhard J Eigl, Krista Noonan, Deepa Wadhwa, Andrew Attwell, Bruce Keith, Susan L Ellard, Lyly Le, Martin E Gleave, Alexander W Wyatt, Kim N Chi
| Article suivant Article suivant
  • Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
  • Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im, Korean Cancer Study Group (KCSG), HK Ahn, EK Cho, IH Park, KS Lee, SS Sim, SJ Hong, MH Chang, JH Kim, YJ Kim, SH Kim, KJ Suh, YH Park, WY Park, YL Choi, JH Yu, YH Im, JS Ahn, JY Hur, SH Park, JY Kim, SJ Nam, JE Lee, SW Kim, SK Lee, SA Im, MS Kim, TY Kim, DY Oh, TY Kim, KH Lee, DW Lee, HJ Kim, KH Jung, SB Kim, JH Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, KE Lee, HJ Kim, MH Lee, JH Cho, JH Lim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.